CGM Trust’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CGM Trust’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$19.4M	Buy	+250,000	New	+$17.2M	2.03%	22

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

CGM Trust's HZNP Position: Q3 2020 in Review

CGM Trust opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2020: 250,000 shares worth $19.4M. The stake represents 2.03% of the portfolio and ranks #22 among its holdings.

433 funds tracked by Wall St. Rank hold HZNP as of Q3 2020.

CGM Trust held 250,000 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $19.4M as of Q3 2020.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new CGM Trust position in Q3 2020.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 2.03% of CGM Trust's portfolio in Q3 2020, its #22 holding.
433 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2020.

Based on CGM Trust's 13F filing for Q3 2020, filed 12 Nov 2020.